1. Amaze approved a 1-for-23 reverse stock split to meet NYSE minimum price requirements. 2. Stockholders elected all director nominees until the 2026 Annual Meeting. 3. Authorized stock adjustments include conversion of multiple preferred stock series. 4. The number of authorized common shares was not increased as proposed. 5. Stockholders ratified auditor appointment for fiscal year 2025.

1. Crown announced a merger agreement with Crown EK Acquisition LLC. 2. Tender offer at $3.15 per share will start in 15 business days. 3. Transaction approved by independent directors and deemed fair for stockholders. 4. Closing expected promptly after completing the tender offer. 5. Future performance relies on market and stockholder acceptance.

1. Sound Group announces $4 million share repurchase program. 2. CEO emphasizes commitment to sustainable value for shareholders. 3. Repurchases may vary based on market conditions and share price. 4. Company plans to fund repurchases using cash reserves or future earnings. 5. Sound Group focuses on expanding audio platform and user engagement.

1. Alarum upgrades second quarter 2025 revenue to approximately $8.8 million. 2. Adjusted EBITDA expectations increase to $1.0 to $1.5 million. 3. Higher customer demand drives growth in product usage. 4. Market remains highly dynamic and unpredictable, indicating potential volatility. 5. Forward-looking statements highlight risks affecting future performance.

1. 51Talk's Q1 2025 gross billings grew 74.6% year-over-year. 2. Net revenues increased by 93.1%, reaching $18.2 million. 3. Active student numbers surged 75.5%, reaching approximately 81,100. 4. Operating loss narrowed to $1.3 million from $4 million last year. 5. Q2 2025 guidance suggests continued growth in gross billings.

1. Elevation Oncology agreed to a merger with Concentra for $0.36 per share. 2. Stockholders may receive contingent value rights tied to future transactions. 3. The merger is expected to close in July 2025. 4. Elevation's Board unanimously recommends the acquisition as beneficial for stockholders. 5. Tender offer by Concentra will begin by June 2025.

1. PPIH's Q1 sales increased by 36% year-over-year to $46.7 million. 2. Net income surged to $5.0 million, up 243% from last year. 3. Current backlog stands at $131.1 million, down from January but up 108% YoY. 4. Positive momentum in North America and MENA regions is expected to continue. 5. PPIH's performance is the best since the transition from MFRI in 2017.

1. DBI reported Q1 2025 net sales down 8% year-over-year. 2. CEO mentioned focus on cost control and preserving margins amidst market volatility. 3. Cost-saving measures may yield $20M to $30M in 2025. 4. Full-year 2025 guidance withdrawn due to economic uncertainties. 5. Dividend remains at $0.05 per share, indicating cash flow management.

1. Calavo received a non-binding acquisition proposal at $32 per share. 2. Proposal includes stock and cash, pending due diligence and financing. 3. Board consulting legal and financial advisors for review. 4. No guarantee of transaction; further updates may be limited.

1. Inuvo reaffirms expected revenue growth of at least 25% for Q2. 2. Company completed a 1-for-10 reverse stock split to enhance liquidity. 3. Strategic move aims to attract institutional investors and analysts. 4. CEO cites consecutive record-breaking quarters as a basis for confidence. 5. IntentKey® AI technology positions Inuvo as a leader in AdTech.